Were there any open-market AGIO share purchases or sales in this Form 4?

No open-market purchases or sales are reported. The Form 4 shows equity compensation grants and the conversion of restricted stock units into common shares. These are non-cash compensation and vesting events, not discretionary trades in the open market.

Agios director receives options and RSU awards

AGIOS PHARMACEUTICALS, INC. director Kaye I. Foster-Cheek reported routine equity compensation and an option-related share delivery.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

AGIOS PHARMACEUTICALS, INC. director Kaye I. Foster-Cheek reported routine equity compensation and an option-related share delivery. On June 18, 2026, she exercised restricted stock units covering 2,816 shares of common stock, increasing her direct holdings to 10,284 shares. She also received a grant of 14,950 stock options with a $34.16 exercise price, expiring on June 18, 2036, and a separate award of 2,927 restricted stock units that will vest in full on June 18, 2027. In addition, 2,200 shares are held indirectly through the Foster Family Revocable Trust. These movements reflect compensation and conversions rather than open-market buying or selling.

Insider Trade Summary

2,816 shares exercised/converted

Exercise 5 txns

Insider Foster-Cheek Kaye I

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted stock units	2,816	$0.00	$0.00
Grant/Award	Restricted stock units	2,927	$0.00	$0.00
Grant/Award	Stock options (right to buy)	14,950	$0.00	$0.00
Exercise	Common stock	2,816	$0.00	$0.00
holding	Common stock	--	--	--

Holdings After Transaction: Restricted stock units — 2,927 contracts (Direct); Stock options (right to buy) — 14,950 contracts (Direct); Common stock — 10,284 shares (Direct); Common stock — 2,200 shares (Indirect, By Foster Family Revocable Trust)

Footnotes (4)

F1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2. The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F3. The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F4. These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Key Figures

RSU shares converted: 2,816 shares Direct common shares held: 10,284 shares Indirect common shares held: 2,200 shares +3 more

6 metrics

RSU shares converted 2,816 shares Restricted stock units converted to common stock on June 18, 2026

Direct common shares held 10,284 shares Total direct ownership after June 18, 2026 transactions

Indirect common shares held 2,200 shares Held through Foster Family Revocable Trust

Stock options granted 14,950 options at $34.16 Options granted June 18, 2026, expiring June 18, 2036

New RSUs granted 2,927 units Restricted stock units granted June 18, 2026 vesting June 18, 2027

RSU grant vesting schedule 100% on June 18, 2027 Vesting for 2,927 restricted stock units

Key Terms

Restricted stock units, Stock options (right to buy), Exercise or conversion of derivative security, Grant, award, or other acquisition, +1 more

5 terms

Restricted stock units financial

"Each restricted stock unit represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock options (right to buy) financial

"Stock options (right to buy) with an exercise price of 34.1600"

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Foster Family Revocable Trust financial

"nature_of_ownership: By Foster Family Revocable Trust"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did AGIO director Kaye I. Foster-Cheek receive?

Kaye I. Foster-Cheek received 14,950 stock options and 2,927 restricted stock units. The options have a $34.16 exercise price and vest in 2027, while the new RSUs also vest in full on June 18, 2027 as part of director compensation.

How many AGIOS PHARMACEUTICALS (AGIO) shares does the director now hold directly?

After the June 18, 2026 transactions, Kaye I. Foster-Cheek holds 10,284 shares of common stock directly. This includes 2,816 shares delivered upon the vesting and conversion of previously granted restricted stock units into common shares on that date.

What happened to the previously granted AGIO restricted stock units?

Previously granted restricted stock units for 2,816 underlying shares vested in full on June 18, 2026. Those vested RSUs were converted into the same number of common shares, which were then added to Kaye I. Foster-Cheek’s direct ownership position in Agios Pharmaceuticals.

When do Kaye I. Foster-Cheek’s new AGIO RSUs and options vest and expire?

The new restricted stock units granted June 18, 2026 vest in full on June 18, 2027. The 14,950 stock options granted the same day also vest 100% on June 18, 2027 and carry an expiration date of June 18, 2036, according to the filing.

Does Kaye I. Foster-Cheek hold any AGIO shares indirectly?

Yes. In addition to her direct holdings, 2,200 Agios Pharmaceuticals common shares are held indirectly. These shares are owned through the Foster Family Revocable Trust, as indicated by the nature of ownership disclosure in the Form 4 insider filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/23/2026 - 05:23 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Foster-Cheek Kaye I

(Last)

(First)

(Middle)

C/O AGIOS PHARMACEUTICALS, INC.

88 SIDNEY STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02139

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock	06/18/2026		M		2,816	A	$0	10,284	D
Common stock								2,200	I	By Foster Family Revocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted stock units	⁽¹⁾	06/18/2026		M			2,816	⁽²⁾	⁽²⁾	Common stock	2,816	$0	0	D
Restricted stock units	⁽¹⁾	06/18/2026		A		2,927		⁽³⁾	⁽³⁾	Common stock	2,927	$0	2,927	D
Stock options (right to buy)	$34.16	06/18/2026		A		14,950		⁽⁴⁾	06/18/2036	Common stock	14,950	$0	14,950	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

2. The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

3. The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

4. These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Remarks:

	/s/ William Cook, as Attorney-in-fact for Kaye Foster	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR